Efficacy of pertuzumab and trastuzumab as first line treatment in patients with HER2-positive metastatic breast cancer
Other Title(s)
فعالية (البيرتوزوماب+ التراستوزوماب) كخط علاجي أول عند مريضات سرطان الثدي النقيلي إيجابيات ال HER2
Author
Source
Damascus University Journal for Medical Sciences
Issue
Vol. 38, Issue 1 (31 Mar. 2022), pp.263-270, 8 p.
Publisher
Publication Date
2022-03-31
Country of Publication
Syria
No. of Pages
8
Main Subjects
Abstract EN
Background: Pertuzumab, a humanized monoclonal antibody, binds the HER2 extracellular domain (subdomain II), and has a complementary action to trastuzumab that binds to different HER2 domains.
These two antibodies, when given together, provide a dual inhibition of receptor dimerization and greater anti-tumor activity.
This study is the first to report results of these two antibodies as first line in HER2+ MBC, at Albairouni university hospital.
Patients and methods: Patients with HER2+ locally advanced or metastatic breast cancer received pertuzumab plus trastuzumab plus chemotherapy (either docetaxel or vinorelbine) as first-line treatment until the time of disease progression or the development of unmanageable toxicity.
The primary end point assessed the objective response and clinical benefit.
Results: In the intention-to-treat population of 65 evaluable patients, clinical benefit rate and objective response rate were 95% and 81.4%, respectively.
In the subgroups, patients had similar clinical benefit with first-line treatment of docetaxel or vinorelbine combined with trastuzumab and pertuzumab (96.7% vs.
94%, respectively).
Conclusion: Our results show a pronounced improvement in objective response and clinical benefit when adding pertuzumab to trastuzumab, and chemotherapy in patients with HER2-positive metastatic breast cancer.
Oral vinorelbine should be highly considered for this combination.
American Psychological Association (APA)
Saifu, Mahir. 2022. Efficacy of pertuzumab and trastuzumab as first line treatment in patients with HER2-positive metastatic breast cancer. Damascus University Journal for Medical Sciences،Vol. 38, no. 1, pp.263-270.
https://search.emarefa.net/detail/BIM-1431640
Modern Language Association (MLA)
Saifu, Mahir. Efficacy of pertuzumab and trastuzumab as first line treatment in patients with HER2-positive metastatic breast cancer. Damascus University Journal for Medical Sciences Vol. 38, no. 1 (2022), pp.263-270.
https://search.emarefa.net/detail/BIM-1431640
American Medical Association (AMA)
Saifu, Mahir. Efficacy of pertuzumab and trastuzumab as first line treatment in patients with HER2-positive metastatic breast cancer. Damascus University Journal for Medical Sciences. 2022. Vol. 38, no. 1, pp.263-270.
https://search.emarefa.net/detail/BIM-1431640
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 269-270
Record ID
BIM-1431640